Last updated on January 2020

A Study to Assess Efficacy and Safety of SER 287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Brief description of study

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER287 in Adults with Active Mild-to-Moderate Ulcerative Colitis

Detailed Study Description

This is a Phase 2B randomized, double-blind, placebo-controlled, multiple dose, multicenter study designed to evaluate the efficacy, safety and microbiome alterations associated with two dose levels of SER-287, after pre-treatment with vancomycin, in adult subjects, age 18-80, with active mild-to-moderate ulcerative colitis (UC).

Clinical Study Identifier: NCT03759041

Find a site near you

Start Over

(Investigator site)

Great Neck, NY United States
  Connect »

(Investigator site)

New Hyde Park, NY United States
  Connect »